Hervé Hoppenot

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015.

Since 2014, the company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation & Autoimmunity and revenue has increased by nearly 600% with the addition of five new sources of revenue.

With a goal to deliver medicines to patients worldwide, Incyte has expanded geographically and has operations in North America, Europe and Asia.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. He began his career at Novartis in 2003 as Chief Commercial Officer and later became President in 2010. Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.